Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Compass Pathways (Nasdaq: CMPS) announced that management will attend Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, featuring a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026.
According to Compass Pathways, a live audio webcast and 30-day replay for each event will be available on the Investors “Events” page. The company is developing its investigational COMP360 psilocybin treatment for treatment-resistant depression and post-traumatic stress disorder, with FDA Breakthrough Therapy and UK ILAP designations for TRD.
Compass Pathways (Nasdaq: CMPS) announced it is working with the U.S. Department of Veterans Affairs on PIVOT, a multi-site, double-blind, randomized controlled trial of its investigational COMP360 psilocybin in veterans with treatment-resistant depression (TRD), including those with concurrent post-traumatic stress disorder (PTSD).
The VA-led study will compare two COMP360 dose levels, with an option for a second open-label administration after four weeks. The primary endpoint is depression severity measured by the MADRS scale, with secondary outcomes including PTSD symptoms, tolerability, and patient-reported depression. Compass will donate COMP360 and provide training materials, guidance and consultation for investigators across five VA sites.
Compass Pathways (Nasdaq: CMPS) granted new employee equity awards under its 2026 Inducement Plan to fourteen newly hired non-executive employees. On August 3, 2026, the company issued options to purchase an aggregate of 139,355 shares and restricted share units or UK nominal cost options covering 66,300 shares.
The options have an exercise price of $11.25, equal to the Nasdaq closing price on the grant date, and vest over four years (25% after one year, then monthly over three years), subject to continued employment. RSUs and nominal cost options vest in four equal annual installments. According to Compass Pathways, the awards were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment, and complement its focus on developing COMP360 psilocybin for treatment-resistant depression and PTSD.
Compass Pathways (Nasdaq: CMPS) reported second quarter and first half 2026 results and detailed progress on COMP360 psilocybin therapy for treatment-resistant depression (TRD) and PTSD. Two positive Phase 3 TRD trials showed rapid onset and durable benefit through at least 6 months, with clinically meaningful MADRS reductions observed from the day after dosing and maintained on average to Week 26. COMP360 was generally well tolerated, with mostly transient, dosing-day adverse events and low serious adverse event rates.
According to Compass, rolling NDA submission and initial FDA review for COMP360 are underway, with final submission on track for Q4 2026, supported by a National Priority Voucher that may shorten review. Commercial launch is expected in first half 2027, subject to FDA approval and DEA rescheduling. A late-stage PTSD trial is ongoing. Q2 2026 research and development expense was $29.2 million and general and administrative expense was $23.2 million. Net loss was $253.8 million, or $1.88 per share, largely driven by a $205.6 million non-cash fair value loss on warrants. Cash and cash equivalents were $433.3 million and debt was $50.7 million at June 30, 2026, and Compass expects its cash to fund operations into 2028.
Compass Pathways (Nasdaq: CMPS) will release its second quarter and first half 2026 financial results for the period ended June 30, 2026, on August 5, 2026. Management will host a conference call at 8:00 am ET (1:00 pm UK), with a live webcast available on the company’s website and archived for 30 days.
Compass Pathways is developing COMP360 psilocybin, a proprietary investigational treatment for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 has FDA Breakthrough Therapy and UK ILAP designations for TRD, and is being studied in large clinical programs in TRD and a late-stage trial in PTSD.
Compass Pathways (Nasdaq: CMPS) announced publication in the Journal of Psychopharmacology of a post-hoc analysis of monitoring and support methods used in an open-label Phase 2 trial of investigational COMP360 synthetic psilocybin in patients with post-traumatic stress disorder (PTSD).
The analysis of documented speech between patients and support providers during treatment administration sessions found that about 78% of session time was spent in silence and that interactions were minimal and non-directive. Patients mainly linked support to presence, availability, reassurance and validation, with support providers often perceived as a reliable but largely background resource. According to Compass Pathways, this limited and non-directive support distinguishes COMP360 trial monitoring from conventional psychotherapy, supports a self-directed psychedelic experience, and underpins a standardized training and mentoring program used across COMP360 trials in treatment-resistant depression (TRD) and PTSD.
Compass Pathways (Nasdaq: CMPS) reported 26-week Phase 3 COMP006 data for COMP360 psilocybin in treatment-resistant depression (TRD). In a highly chronic TRD population, 39% on 25 mg achieved ≥25% MADRS reduction at Week 6 and maintained benefit, on average, through Week 26, with a generally well-tolerated safety profile.
Nearly 30% of Week 6 responders entered remission after retreatment. A rolling NDA with the FDA is underway, with final submission targeted for Q4 2026 and a potential U.S. launch in the first half of 2027, subject to approval and DEA rescheduling.
Compass Pathways (Nasdaq: CMPS) granted new equity awards under its 2026 Inducement Plan to eight newly hired non-executive employees. Awards, granted on July 1, 2026, include options for 63,685 shares and restricted share units or UK nominal cost options for 30,300 shares.
The options have a $13.29 exercise price, matching the Nasdaq closing price on the grant date, and vest over four years (25% after one year, then monthly over three years). RSUs and nominal cost options vest in four equal annual installments. According to Compass, these awards were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment.
Compass Pathways (Nasdaq: CMPS) granted equity awards under its 2026 Inducement Plan to 17 newly hired non-executive employees. Awards, granted on June 1, 2026, include options for 157,000 shares at $14.19 and RSUs/nominal cost options for 74,700 shares, all vesting over four years under Nasdaq Rule 5635(c)(4).
Compass Pathways (Nasdaq: CMPS) elected Kathleen Tregoning to its Board of Directors at the annual general meeting. She will serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee.
According to Compass Pathways, Tregoning brings extensive biopharma experience, including senior roles at Cerevel Therapeutics, Sanofi and Biogen, plus health policy work in the U.S. Congress. The company highlights progress for its investigational therapy COMP360, including two Phase 3 trials that met their primary endpoint and a rolling NDA submission and review for treatment-resistant depression.